German China

Switzerland: Services Agreement Lonza and Bioqube Join Forces for Development and Manufacture of Biologics and Small Molecules

From MA Alexander Stark

Within the framework of a five-year services agreement, Lonza and Bioqube want to provide for the development and manufacturing of biologics and small molecules for portfolio companies of Bioqube. The offering is to accelerate timelines for the development and manufacturing of molecules and disruptive technologies.

Related Vendors

Lonza and Bioqube Ventures signed a framework agreement for the future development and manufacture of biologics and small molecules for Bioqube’s portfolio companies.
Lonza and Bioqube Ventures signed a framework agreement for the future development and manufacture of biologics and small molecules for Bioqube’s portfolio companies.
(Source: Lonza)

Basel/Switzerland — Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, and Lonza announced a framework agreement covering a strategic collaboration for the development and manufacturing of biologics and small molecules.

The agreement was developed to support the unique needs of the venture capital company (VC) and its portfolio companies looking to simplify the development of their molecules. Under the terms of the agreement, Lonza will support Bioqube Ventures during the due diligence of candidate biotechs and provide a tailored offering of advice and services to its portfolio companies.

The offering comprises Lonza's expertise and technology that is designed to accellarate timelines while mitigating risks of the development and manufacturing of molecules ranging from monoclonal antibodies, complex proteins, and small molecules to antibody-drug conjugates. The holistic approach to drug substance and drug product development and manufacturing across various platforms simplifies the supply chain, reduces process complexity, and allows for a shortened development timelines, the company states.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:47869251)